Team
Meet the founding partners:
Wolfgang Hierneis
Managing Director
Wolfgang Hierneis
Wolfgang Hierneis has more than 25 years of experience in financial advisory and strategic consultancy with start-up companies and SMEs. Prior to setting up his own business in 1998 he worked with a German private equity firm. He graduated as a master in economics at the University of Hamburg and completed a bank-traineeship. He is one of the founders of Lipocyte Biomed and his main tasks are strategic management and finance.
Dr. Helge W. Thies
Head of Research and Development
He studied biology at the University of Bremen and graduated with a diploma (master) in 2009. After gaining his diploma, he worked as a research assistant for the Center of Human Genetics (ZHG) in Bremen and for a Dutch biotech company. Dr. Thies’ scientific research focused on mRNA analysis with regard to adipogenesis, dysfunctional adipose tissue and mesenchymal stem cell differentiation. He obtained his PhD in biology at the University of Bremen in 2014.
Dr. Markus Klemke
Head of Laboratory
He studied biology at the University of Bremen and graduated with a diploma (master) in 2006. Subsequently he worked as a researcher for a biotech company in Bremen, where he performed genetic analyses of different human tumours. Dr. Klemke was the head scientist in a research project for cancer markers in cooperation with a leading, globally acting German biotech company. He obtained his PhD in biology at the University of Bremen in 2014.
Uwe Jensen
Managing Director
He is an expert in national and international R&D processes focussing on start-up and growth companies. Before setting up a consulting firm he worked for state owned companies and in the private oil and gas sector. He got his diploma in physics at the University of Göttingen and was trained in technical impact assessment, environmental protection and energy saving measures.
Breaking new ground for
diagnostics, therapeutics and prevention
Diagnostics
mRNA-analysis of the SAT offers deep and completely new insights into the energy metabolism. Especially with metabolic diseases the current dynamics of the body and influences over life-time play a far greater role than genetic dispositions
Read moreTherapeutics
The key to successful treatment of metabolic diseases lies in the intervention with disease-causing on-going biological processes. As the mRNA of the SAT are to a great extent the drivers of pathology of these diseases, they offer a strong lever for therapy.
Read morePrevention
A great advantage of mRNA-analysis of the subcutaneous adipose tissue lies in the very early detection of unhealthy developments of the metabolism long before any signs can be seen in blood-analysis or any symptoms become apparent. It is, therefore, a powerful component in preventive personalised medicine.
Read more